Last reviewed · How we verify
Cannabis oil
Cannabis oil contains cannabinoids (primarily THC and CBD) that interact with endocannabinoid receptors (CB1 and CB2) throughout the central and peripheral nervous systems to modulate pain, inflammation, and other physiological processes.
Cannabis oil contains cannabinoids (primarily THC and CBD) that interact with endocannabinoid receptors (CB1 and CB2) throughout the central and peripheral nervous systems to modulate pain, inflammation, and other physiological processes. Used for Chronic pain, Chemotherapy-induced nausea and vomiting, Multiple sclerosis-related spasticity.
At a glance
| Generic name | Cannabis oil |
|---|---|
| Also known as | MPL-005, Extrato de Cannabis sativa GreenCare 79.14 mg/mL, Avidekel Oil |
| Sponsor | Assaf-Harofeh Medical Center |
| Drug class | Phytocannabinoid preparation |
| Target | CB1 receptor, CB2 receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology, Pain Management, Oncology (supportive care) |
| Phase | FDA-approved |
Mechanism of action
The active cannabinoids in cannabis oil bind to CB1 receptors in the brain and nervous system and CB2 receptors in immune cells and peripheral tissues. This activation modulates neurotransmitter release, reduces inflammatory cytokine production, and alters pain signal processing. The specific therapeutic effects depend on the THC:CBD ratio and the condition being treated.
Approved indications
- Chronic pain
- Chemotherapy-induced nausea and vomiting
- Multiple sclerosis-related spasticity
- Epilepsy (particularly in pediatric populations)
Common side effects
- Dizziness
- Dry mouth
- Fatigue
- Impaired cognition
- Anxiety or paranoia (THC-dominant formulations)
Key clinical trials
- Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden (PHASE2)
- Cannabis and Polysubstance Use: Response Inhibition and Stress Exposure (PHASE1)
- Cannabidiol for Reduction of Brain Neuroinflammation (PHASE2)
- Analysis of the Therapeutic and Clinical Profile of Cannabinoid Treatments: A Real-World Study
- Cannabinoids as a Treatment for Insomnia in Major Depression (PHASE2)
- Cannabis (THC vs. CBD) in Multiple Sclerosis (PHASE2)
- Pilot Study of MC in Paediatric Palliative Care (PHASE1, PHASE2)
- Reducing Pain and Opioid Use With CBD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cannabis oil CI brief — competitive landscape report
- Cannabis oil updates RSS · CI watch RSS
- Assaf-Harofeh Medical Center portfolio CI